Revolution Medicines Inc. (RVMD)
$153.48
$4.25
(2.85%)
As on 12-Jun-2026 13:38EDT
Market cap
$31,726 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
22
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-54 %
-
Industry P/E
--
-
EV/EBITDA
-9.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.1
-
Face value
--
-
Shares outstanding
212,596,462
7 Years Aggregate
CFO
$-895.77 Mln
EBITDA
$-1,140.87 Mln
Net Profit
$-1,093.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| 92.7 | 6.5 | 54.1 | 276.3 | 81.8 | 35.0 | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| 82.1 | 52.0 | 20.4 | -5.4 | -36.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
|
153.5 | 31,725.8 | 0.0 | -1,371.7 | -- | -88.6 | -- | 22.0 |
| 0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 | |
| 0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 |
Shareholding Pattern
View DetailsAbout Revolution Medicines (RVMD)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as... monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Read more
-
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
-
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Revolution Medicines (RVMD)
What is the current share price of Revolution Medicines Inc (RVMD) Today?
The share price of Revolution Medicines Inc (RVMD) is $153.48 (NASDAQ) as of 12-Jun-2026 13:38 EDT. Revolution Medicines Inc (RVMD) has given a return of 81.81% in the last 3 years.
What is the current PB & PE ratio of Revolution Medicines Inc (RVMD)?
Since, TTM earnings of Revolution Medicines Inc (RVMD) is negative, P/E ratio is not available.
The P/B ratio of Revolution Medicines Inc (RVMD) is 22.04 times as on 05-Jun-2026, a 442 premium to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.38
|
9.28
|
|
2024
|
-12.25
|
3.24
|
|
2023
|
-7.43
|
1.77
|
|
2022
|
-7.76
|
2.82
|
|
2021
|
-9.82
|
3.05
|
What is the 52 Week High and Low of Revolution Medicines Inc (RVMD)?
The 52-week high and low of Revolution Medicines Inc (RVMD) are Rs 166.50 and Rs 34.00 as of 13-Jun-2026.
What is the market cap of Revolution Medicines Inc (RVMD)?
Revolution Medicines Inc (RVMD) has a market capitalisation of $ 31,726 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Revolution Medicines Inc (RVMD)?
Before investing in Revolution Medicines Inc (RVMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.